Search

Your search keyword '"Voigt, Tobias"' showing total 290 results
Start Over Author "Voigt, Tobias"
290 results on '"Voigt, Tobias"'

9. Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction

Author

Zúñiga, Luis Alejandro, Leßmann, Torben, Uppal, Karan, Bisek, Nicola, Hong, Enping, Rasmussen, Caroline E., Karlsson, Jens-Jakob, Zettler, Joachim, Holten-Andersen, Lars, Bang, Kathy, Thakar, Dhruv, Lee, Yu-Chi, Martinez, Salomon, Sabharwal, Simran Singh, Stark, Sebastian, Faltinger, Frank, Kracker, Oliver, Weisbrod, Samuel, Müller, Robin, Voigt, Tobias, Bigott, Kornelia, Tabrizifard, Mohammad, Breinholt, Vibeke Miller, Mirza, Amer M., Rosen, David B., Sprogøe, Kennett, and Punnonen, Juha

Published
2022
Full Text
View/download PDF

16. Overview of Technology and Functionality Standards for Industry 4.0 and Digitalization in Mechanical Engineering.

Author

Staiger, Matthias and Voigt, Tobias

Subjects
MECHANICAL engineering, MECHANICAL engineers, INDUSTRY 4.0, COMMUNICATIONS software, TELECOMMUNICATION, DIGITAL technology, MACHINE-to-machine communications, KNOWLEDGE gap theory
Abstract

This paper concerns the identification of current communication technologies and software functionalities from the field of digitalization and Industry 4.0, from the point of view of benefits and applicability for the machine manufacturer. To identify the relevant technologies and functionalities, research was carried out in both the descriptive and statistical literature. As a result, both technologies that are currently the most widely distributed, as well as eleven IT functionalities relevant to mechanical engineers, were identified and described in terms of their application and implementation. Furthermore, a knowledge gap was identified in the area of industry transfer in the field of Industry 4.0/digitalization. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Distance Based Feature Construction in a Setting of Astronomy

Author

Voigt, Tobias, Fried, Roland, Bock, Hans-Hermann, Editor-in-chief, Gaul, Wolfgang, Editor-in-chief, Baier, Daniel, Series editor, Vichi, Maurizio, Editor-in-chief, Critchley, Frank, Series editor, Decker, Reinhold, Series editor, Diday, Edwin, Series editor, Greenacre, Michael, Series editor, Lauro, Carlo Natale, Series editor, Meulman, Jacqueline, Series editor, Monari, Paola, Series editor, Nishisato, Shizuhiko, Series editor, Ohsumi, Noboru, Series editor, Opitz, Otto, Series editor, Ritter, Gunter, Series editor, Schader, Martin, Series editor, Weihs, Claus, Editor-in-chief, Lausen, Berthold, editor, Krolak-Schwerdt, Sabine, editor, and Böhmer, Matthias, editor

Published
2015
Full Text
View/download PDF

31. Gamma-Hadron-Separation in the MAGIC Experiment

Author

Voigt, Tobias, Fried, Roland, Backes, Michael, Rhode, Wolfgang, Bock, Hans-Hermann, Editor-in-chief, Gaul, Wolfgang, Editor-in-chief, Baier, Daniel, Series editor, Vichi, Maurizio, Editor-in-chief, Critchley, Frank, Series editor, Decker, Reinhold, Series editor, Diday, Edwin, Series editor, Greenacre, Michael, Series editor, Lauro, Carlo Natale, Series editor, Meulman, Jacqueline, Series editor, Monari, Paola, Series editor, Nishisato, Shizuhiko, Series editor, Ohsumi, Noboru, Series editor, Opitz, Otto, Series editor, Ritter, Gunter, Series editor, Schader, Martin, Series editor, Weihs, Claus, Editor-in-chief, Spiliopoulou, Myra, editor, Schmidt-Thieme, Lars, editor, and Janning, Ruth, editor

Published
2014
Full Text
View/download PDF

39. Additional file 4 of Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction

Author

Zúñiga, Luis Alejandro, Leßmann, Torben, Uppal, Karan, Bisek, Nicola, Hong, Enping, Rasmussen, Caroline E., Karlsson, Jens-Jakob, Zettler, Joachim, Holten-Andersen, Lars, Bang, Kathy, Thakar, Dhruv, Lee, Yu-Chi, Martinez, Salomon, Sabharwal, Simran Singh, Stark, Sebastian, Faltinger, Frank, Kracker, Oliver, Weisbrod, Samuel, Müller, Robin, Voigt, Tobias, Bigott, Kornelia, Tabrizifard, Mohammad, Breinholt, Vibeke Miller, Mirza, Amer M., Rosen, David B., Sprogøe, Kennett, and Punnonen, Juha

Abstract

Additional file 4: Figure S3. TransCon TLR7/8 Agonist inhibited MC38 tumor growth in a dose-dependent manner. Female C57BL/6 mice were SC implanted with 5 x 105 CT26 tumor cells in their flank. When tumors were grown to a mean tumor volume of ~100 mm3, mice were randomized into treatment cohorts (Day 0; n = 20-22/group). On the same day of randomization, animals received either empty hydrogel (TransCon Vehicle) or 25 or 134 μg (eq. of resiquimod) of TransCon TLR7/8 Agonist as a single intratumoral dose (arrow). Values are represented as mean tumor volume ± SEM. On Day 18, * = p

Published
2022
Full Text
View/download PDF

40. Additional file 1 of Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction

Author

Zúñiga, Luis Alejandro, Leßmann, Torben, Uppal, Karan, Bisek, Nicola, Hong, Enping, Rasmussen, Caroline E., Karlsson, Jens-Jakob, Zettler, Joachim, Holten-Andersen, Lars, Bang, Kathy, Thakar, Dhruv, Lee, Yu-Chi, Martinez, Salomon, Sabharwal, Simran Singh, Stark, Sebastian, Faltinger, Frank, Kracker, Oliver, Weisbrod, Samuel, Müller, Robin, Voigt, Tobias, Bigott, Kornelia, Tabrizifard, Mohammad, Breinholt, Vibeke Miller, Mirza, Amer M., Rosen, David B., Sprogøe, Kennett, and Punnonen, Juha

Abstract

Additional file 1: Table S1A. Flow cytometry reagents for analysis of mouse blood. Table S1B. Populations analyzed in mouse blood. Table S2A. Flow cytometry reagents for analysis of antigen presenting cells from mouse tDLN and tumor cell samples. Table S2B. Antigen presenting cell populations analyzed in mouse tDLN and tumor cell samples. Table S3A. Flow cytometry reagents for analysis of lymphoid cells from mouse tDLN and tumor cell samples. Table S3B. Lymphoid cell populations analyzed in mouse tDLN and tumor cell samples. Table S4A. Flow cytometry reagents for analysis of AH1-tetramer+ cells from mouse tumor cell samples. Table S4B. AH1-tetramer+ cell populations analyzed in mouse tumor samples

Published
2022
Full Text
View/download PDF

41. Additional file 3 of Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction

Author

Zúñiga, Luis Alejandro, Leßmann, Torben, Uppal, Karan, Bisek, Nicola, Hong, Enping, Rasmussen, Caroline E., Karlsson, Jens-Jakob, Zettler, Joachim, Holten-Andersen, Lars, Bang, Kathy, Thakar, Dhruv, Lee, Yu-Chi, Martinez, Salomon, Sabharwal, Simran Singh, Stark, Sebastian, Faltinger, Frank, Kracker, Oliver, Weisbrod, Samuel, Müller, Robin, Voigt, Tobias, Bigott, Kornelia, Tabrizifard, Mohammad, Breinholt, Vibeke Miller, Mirza, Amer M., Rosen, David B., Sprogøe, Kennett, and Punnonen, Juha

Abstract

Additional file 3: Figure S2. TransCon TLR7/8 Agonist inhibited CT26 tumor growth in a dose-dependent manner. Female BALB/c mice were SC implanted with 3 x 105 CT26 tumor cells in their flank. When tumors were grown to a mean tumor volume of ~115 mm3, mice were randomized into treatment cohorts (Day 0; n = 17/group). The day following randomization, animals received either empty hydrogel (TransCon Vehicle) or 5, 20, 80, or 200 μg (eq. of resiquimod) of TransCon TLR7/8 Agonist as a single intratumoral dose (arrow). Values are represented as mean tumor volume ± SEM. On Day 10, * = p

Published
2022
Full Text
View/download PDF

42. Additional file 2 of Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction

Author

Zúñiga, Luis Alejandro, Leßmann, Torben, Uppal, Karan, Bisek, Nicola, Hong, Enping, Rasmussen, Caroline E., Karlsson, Jens-Jakob, Zettler, Joachim, Holten-Andersen, Lars, Bang, Kathy, Thakar, Dhruv, Lee, Yu-Chi, Martinez, Salomon, Sabharwal, Simran Singh, Stark, Sebastian, Faltinger, Frank, Kracker, Oliver, Weisbrod, Samuel, Müller, Robin, Voigt, Tobias, Bigott, Kornelia, Tabrizifard, Mohammad, Breinholt, Vibeke Miller, Mirza, Amer M., Rosen, David B., Sprogøe, Kennett, and Punnonen, Juha

Abstract

Additional file 2: Figure S1. Consistent resiquimod release in vitro from TransCon TLR7/8 Agonist in the pH range between 6.8 and 7.8. A suspension of TransCon TLR7/8 Agonist (nominal 47 μg eq. of resiquimod) in 60 mM phosphate buffer was incubated at 37 °C at various pH levels. Samples of the supernatant were withdrawn at various times and the resiquimod content was determined. Values are represented as mean percentage from 2 experiments of resiquimod release of total resiquimod loaded on the hydrogel. Release half-lives were determined following a first-order fit of the data.

Published
2022
Full Text
View/download PDF

50. Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction.

Author

Zúñiga, Luis Alejandro, Leßmann, Torben, Uppal, Karan, Bisek, Nicola, Hong, Enping, Rasmussen, Caroline E., Karlsson, Jens-Jakob, Zettler, Joachim, Holten-Andersen, Lars, Bang, Kathy, Thakar, Dhruv, Lee, Yu-Chi, Martinez, Salomon, Sabharwal, Simran Singh, Stark, Sebastian, Faltinger, Frank, Kracker, Oliver, Weisbrod, Samuel, Müller, Robin, and Voigt, Tobias

Subjects
TOLL-like receptors, ANTINEOPLASTIC agents, LYMPHATIC metastasis, TUMOR microenvironment, TUMOR growth, T cells
Abstract

Background: Intratumoral (IT) delivery of toll-like receptor (TLR) agonists has shown encouraging anti-tumor benefit in preclinical and early clinical studies. However, IT delivery of TLR agonists may lead to rapid effusion from the tumor microenvironment (TME), potentially limiting the duration of local inflammation and increasing the risk of systemic adverse events. Methods: To address these limitations, TransCon™ TLR7/8 Agonist—an investigational sustained-release prodrug of resiquimod that uses a TransCon linker and hydrogel technology to achieve sustained and predictable IT release of resiquimod—was developed. TransCon TLR7/8 Agonist was characterized for resiquimod release in vitro and in vivo, in mice and rats, and was assessed for anti-tumor efficacy and pharmacodynamic activity in mice. Results: Following a single IT dose, TransCon TLR7/8 Agonist mediated potent tumor growth inhibition which was associated with sustained resiquimod release over several weeks with minimal induction of systemic cytokines. TransCon TLR7/8 Agonist monotherapy promoted activation of antigen-presenting cells in the TME and tumor-draining lymph nodes, with evidence of activation and expansion of CD8+ T cells in the tumor-draining lymph node and TME. Combination of TransCon TLR7/8 Agonist with systemic immunotherapy further promoted anti-tumor activity in TransCon TLR7/8 Agonist-treated tumors. In a bilateral tumor setting, combination of TransCon TLR7/8 Agonist with systemic IL-2 potentiated tumor growth inhibition in both injected and non-injected tumors and conferred protection against tumor rechallenge following complete regressions. Conclusions: Our findings show that a single dose of TransCon TLR7/8 Agonist can mediate sustained local release of resiquimod in the TME and promote potent anti-tumor effects as monotherapy and in combination with systemic immunotherapy, supporting TransCon TLR7/8 Agonist as a novel intratumoral TLR agonist for cancer therapy. A clinical trial to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, as monotherapy and in combination with pembrolizumab, in cancer patients is currently ongoing (transcendIT-101; NCT04799054). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results